Suppr超能文献

中国林州市食管鳞状细胞癌患者的DNA聚合酶β突变与生存情况

DNA polymerase β mutations and survival of patients with esophageal squamous cell carcinoma in Linzhou City, China.

作者信息

Li Min, Zang Wenqiao, Wang Yuanyuan, Ma Yunyun, Xuan Xiaoyan, Zhao Jimin, Liu Lulu, Dong Ziming, Zhao Guoqiang

出版信息

Tumour Biol. 2014 Jan;35(1):553-9. doi: 10.1007/s13277-013-1077-4.

Abstract

Linzhou City in northern China has a high incidence of esophageal squamous cell carcinoma (ESCC). This study retrospectively analyzed the data of 231 cases with ESCC collected from 1998 to 2012. Mutations of DNA polymerase β (polβ) gene in the ESCC samples from patients in Linzhou City were examined by amplifying polβ cDNA by RT-PCR followed by cloning and sequencing. Mutations in polβ were found in 105 cases (45.9%). Nine types of mutations were identified in the polβ cDNA; the most common were 177–234 nt deletion (11.3%), 462 nt G → T (9.1%), and 648 nt G → C (6.9%). Mutations in polβ appeared to be associated with TNM status (P = 0.048). Follow-up data was used for survival analysis. The overall 5-year survival rate of the 231 patients was 37.4%; the rate for patients with wild-type (WT) polβ was 41.8%. Compared with the WT polβ group, the median survival for patients with specific mutations (177–234 nt deletion, 462 nt G → T, or 613 nt A → T) was significantly shorter (all P = 0.000), and the 5-year survival rate decreased to 0%. Patients with the 648 nt G → C mutation had improved survival (P = 0.000) with a 5-year survival rate of 100%. Our results identified nine types of mutations within polβ cDNA in ESCC patients with four mutations related to patient survival.

摘要

中国北方的林州市食管鳞状细胞癌(ESCC)发病率很高。本研究回顾性分析了1998年至2012年收集的231例ESCC患者的数据。通过逆转录聚合酶链反应(RT-PCR)扩增DNA聚合酶β(polβ)基因的cDNA,然后进行克隆和测序,检测林州市ESCC患者样本中polβ基因的突变情况。在105例(45.9%)患者中发现了polβ基因的突变。在polβ cDNA中鉴定出9种类型的突变;最常见的是177-234 nt缺失(11.3%)、462 nt G→T(9.1%)和648 nt G→C(6.9%)。polβ基因的突变似乎与TNM分期有关(P = 0.048)。利用随访数据进行生存分析。231例患者的总体5年生存率为37.4%;野生型(WT)polβ患者的生存率为41.8%。与WT polβ组相比,具有特定突变(177-234 nt缺失、462 nt G→T或613 nt A→T)患者的中位生存期显著缩短(所有P = 0.000),5年生存率降至0%。648 nt G→C突变患者的生存率有所提高(P = 0.000),5年生存率为100%。我们的研究结果在ESCC患者的polβ cDNA中鉴定出9种类型的突变,其中4种突变与患者生存相关。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验